Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Clinical value of metabolic PET parameters of primary vulvar carcinoma
Journal Information
Vol. 40. Issue 6.
Pages 367-371 (November - December 2021)
Share
Share
Download PDF
More article options
Visits
4
Vol. 40. Issue 6.
Pages 367-371 (November - December 2021)
Original Article
Clinical value of metabolic PET parameters of primary vulvar carcinoma
Valor clínico de los parámetros metabólicos del PET del carcinoma vulvar primario
Visits
4
Ahmet Yanarateşa,
Corresponding author
ahmetyanarates@gmail.com

Corresponding author.
, Emine Budaka, Adnan Budakb, Abdurrahman Hamdi Inanb, Ahkam Göksel Kanmazb, Aylin Oralc, Bulent Yazicic
a University of Health Sciences, Izmir Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Department of Nuclear Medicine, Izmir, Turkey
b Tepecik Training and Research Hospital, Department of Obstetrics and Gynecology, Izmir, Turkey
c Ege University Medical Faculty, Department of Nuclear Medicine, Izmir, Turkey
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (4)
Table 1. Patient characteristics.
Table 2. Comparison of survival between the groups.
Table 3. Survival analysis results of age and PET parameters.
Table 4. Comparison of PET parameters in cases grouped according to lymph node metastasis.
Show moreShow less
Abstract
Purpose

We aim to establish the prognostic value of metabolic parameters of the primary tumor in patients diagnosed with vulvar squamous cell carcinoma (VSCC) who underwent a pretreatment F-18 FDG PET/CT scan.

Materials and Methods

This retrospective study included 47 patients with a histopathologically confirmed diagnosis of VSCC, and who underwent a F-18 FDG PET/CT scan prior to treatment. The disease stage and age at diagnosis, and the maximum standardized uptake value (SUVmax), SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) values of the primary tumor, based on a baseline PET scan, were recorded. The relationship between these factors, and progression-free survival (PFS) and overall survival (OS) was evaluated.

Results

The mean age of the 47 study patients was 69.6±1.9 years. Among the patients, 18 were in early stage of the disease and 29 were in the advanced stage. The age, and SUVmax, SUVmean, MTV and TLG values were statistically significantly associated with OS and PFS. Furthermore, it was noted that OS and PFS were significantly longer in the early stage patients than in the advanced stage patients, in patients with a tumor size <4cm than those with a tumor size ≥4cm, and in patients with a negative lymph node metastasis than those with a positive lymph node metastasis.

Conclusion

Our findings suggest that PET parameters are prognostic factors for VSCC. To the best of our knowledge, this study is the first to investigate the prognostic value of the PET parameters of primary tumors in patients with VSCC, and as such, we believe it contributes to literature.

Keywords:
Vulvar carcinoma
PET/CT
SUVmax
MTV
TLG
Resumen
Objetivo

Nuestro propósito es establecer el valor prognóstico de los parámetros metabólicos del tumor primario en pacientes diagnosticadas de carcinoma vulvar de células escamosas (VSCC) en las que se realizó un 18F- FDG PET/TC pretratamiento.

Materiales y métodos

estudio retrospectivo que incluyó 47 pacientes con un diagnóstico histopatológico confirmado de VSCC en las que se realizó un 18F- FDG PET/TC antes del tratamiento. Se registraron la fase de la enfermedad, la edad de diagnóstico y el valor estandarizado de captación máximo (SUVmax), los valore de SUVmean, del volumen de tumor metabólico (MTV) y de la glicólisis total de la lesión (TLG) del tumor primario, según una PET basal. Se evaluó la relación entre estos factores, la supervivencia libre de progresión (PFS) y la supervivencia global (OS).

Resultados

La edad media de las 47 pacientes del estudio era de 69,6±1,9 años. Entre las pacientes, 18 estaban en la fase inicial de la enfermedad y 29 estaban en fase avanzada. La edad y los valores de SUVmax, SUVmean, MTV y TLG estaban asociados de forma estadísticamente significativa con la OS y PFS. Además, se observó que OS y PFS era significativamente mayor en los pacientes en fases iniciales que en las pacientes en fase avanzada; en pacientes con un tamaño del tumor <4cm que en aquellas con un tamaño del tumor de ≥4cm y en pacientes con metástasis de ganglios linfáticos negativa respecto a aquellos con metástasis ganglionar positiva.

Conclusión

Nuestros resultados sugieren que los parámetros del PET son factores pronósticos del VSCC. Hasta donde sabemos, este estudio es el primero en investigar el valor pronóstico de los parámetros PET de los tumores primarios en pacientes con VSCC, y por esta razón, creemos que contribuye a la literatura especializada.

Palabras clave:
Carcinoma vulvar, PET/TC, SUVmax, MTV, TLG

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.remnie.2019.09.005
No mostrar más